BioPharm News

Oct 16, 2018
By BioPharm International Editors
According to CPhI’s annual report, the therapeutic antibody drug conjugates (ADC) market is expected to reach $4 billion by 2023.
Oct 15, 2018
By BioPharm International Editors
The company was awarded for excellence in innovation for Parteck MXP Excipient and modified amino acids.
Oct 15, 2018
By BioPharm International Editors
The company will collaborate with GlycoBac to offer an insect cell line for the development of viral vaccines and gene therapies.
Oct 12, 2018
By BioPharm International Editors
A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.
Oct 12, 2018
By BioPharm International Editors
The company says the new equipment will reduce sample turnaround times and increase variant detection quality and accuracy.
Oct 12, 2018
By BioPharm International Editors
Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab).
Oct 11, 2018
By BioPharm International Editors
Roche has acquired Tusk Therapeutics in a deal worth up to EUR 659 million (US$762 million).
Oct 11, 2018
By BioPharm International Editors
The new facility will include comprehensive mammalian process development and manufacturing capabilities.
Oct 10, 2018
Congress approves bills with provisions important to FDA and industry, some of which reflect continuing concerns about drug pricing and transparency.
Oct 10, 2018
By BioPharm International Editors
The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.
native1_300x100
lorem ipsum